Evidence map›Paper›PMID 25596263›Full record

Trial reportHaematologica2015

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.

Robert Chen, Paul Frankel, Leslie Popplewell, Tanya Siddiqi, Nora Ruel, Arnold Rotter, Sandra H Thomas, Michelle Mott, Nitya Nathwani, Myo Htut and 3 more

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Histone Modifications and Their Targeting in Lymphoid Malignancies.International journal of molecular sciences · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Robert ChenDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA rchen@coh.org.
Paul FrankelDepartment of Biostatistics, City of Hope, Duarte, CA, USA.
Leslie PopplewellDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Tanya SiddiqiDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Nora RuelDepartment of Biostatistics, City of Hope, Duarte, CA, USA.
Arnold RotterDepartment of Radiology, City of Hope, Duarte, CA, USA.
Sandra H ThomasDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Michelle MottDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Nitya NathwaniDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Myo HtutDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Auayporn NademaneeDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
Mark KirschbaumDepartment of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA, USA.
City of Hope · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
NCI NIH HHS K12 CA001727NCI NIH HHS K12CA001727NCI NIH HHS P30 CA033572NCI NIH HHS P30 CA33572
6 · The paper itself

Abstract

This study examines the activity and tolerability of a regimen combining vorinostat and rituximab in patients with indolent B-cell non-Hodgkin lymphoma. A total of 28 patients with newly diagnosed or relapsed/refractory follicular, marginal zone, or mantle cell lymphoma, with 4 or less prior therapies were eligible for this open-label phase II study. Oral vorinostat 200 mg was administered twice daily on days 1-14 along with 375 mg/m(2) of intravenous rituximab on day 1 of a 21-day cycle, continuing until disease progression or unacceptable toxicity. Primary end point was objective response rate, with secondary end points of progression-free survival, time to progression, duration of response, safety, and tolerability. Median follow up was 25.6 months and median number of vorinostat cycles was 11.5. Overall response rate was 46% for all patients, 67% for previously untreated, and 41% for relapsed/refractory patients. Median progression-free survival was 29.2 months for all patients, 18.8 months for previously treated patients, and not reached for untreated patients. The regimen was well tolerated over long treatment periods with the most common grade 3/4 adverse events being asymptomatic thrombosis, neutropenia, thrombocytopenia, lymphopenia, and fatigue. The vorinostat/rituximab combination exhibits activity in indolent B-cell non-Hodgkin lymphoma with an acceptable safety profile and durable responses. Re-treatment was effective in 2 of 3 relapsing responders. This phase II clinical trial was registered at clinicaltrials.gov identifier: 00720876.

Indexed as

Administration, OralAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsDisease ProgressionDrug Therapy, CombinationFemaleFollow-Up StudiesHumansHydroxamic AcidsInjections, IntravenousLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Mantle-CellAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsHydroxamic AcidsRituximabVorinostat

Identifiers

PMID25596263
PMCPMC4349274
OpenAlexW2143161378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.